Switzerland: GeNeuro signs credit agreement with EIB to help fund long-Covid trials


Geneva-based GeNeuro, a biopharmaceutical company developing novel treatments for neurodegenerative and autoimmune diseases, has signed a credit agreement for up to €25m (US$26.4m) with the European Investment Bank (EIB), supported by the InvestEU programme. GeNeuro launched a Phase 2 trial at the end of 2022 to evaluate the clinical efficacy of a six-month treatment with…

You must be a HMI Subscriber to view this content.

Subscribe Now »